Claims
- 1. A compound of the formula:
- A--X.sub.1 --NO.sub.2
- or salts, wherein;
- A=R(COX).sub.t, wherein t=0 or 1;
- X=O, NH, NR.sub.1c, wherein R.sub.1c is a linear or branched C.sub.1 -C.sub.10 alkyl group ##STR11## wherein m and n are an integer from 1 to 6; wherein R.sub.2a is H or CH.sub.3 ; and wherein the linking with X.sub.1 can be in any position of the ring;
- R is: ##STR12## wherein: X.sub.0 =X;
- R.sub.1 is OCOR.sub.3 ; wherein R.sub.3 is methyl, ethyl, linear or branched C.sub.3 -C.sub.5 alkyl, or the residue of an etherocycle with only one ring having 5 or 6 atoms which can be aromatic, partially or completely hydrogenated, containing one or more ethero-atoms selected independently among O, N and S;
- R.sub.2 is hydrogen, hydroxy, halogen, linear or branched C.sub.1-4 alkyl, linear or branched C.sub.1 -C.sub.4 alkoxyl; a linear or branched C.sub.1 -C.sub.4, perflouroalkyl, nitro, amino, mono- or dialkylamine with C.sub.1-4 alkyl; or R.sub.1 and R.sub.2 together are dioxymethylene group;
- n.sub.I is an integer 0 or 1;
- X.sub.1 in the formula A--X.sub.1 --NO.sub.2, is a bivalent connecting bridge selected from the group consisting of --YO-- where Y is a linear or branched C.sub.1-20 alkylene, or a substituted or unsubstituted C.sub.5-7 cycloalkylene; and ##STR13## wherein n is an integer from 1 to 6, R.sub.2a is an defined above; Y is as defined above, and r=0 or 1;
- with the proviso that when X=NH, then Y is only ethylene and R.sub.2 is hydrogen; and with the proviso that R.sub.1 cannot be OCOR.sub.3, in position 2 when R.sub.3 is methyl.
- 2. The compound according to claim 1, wherein R is ##STR14## wherein --X.sub.1 --NO.sub.2 is --CH.sub.2 --ONO.sub.2, --CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 ONO.sub.2, --CH.sub.2 CH.sub.2 ONO.sub.2, --CH.sub.2 CH.sub.2 OCH.sub.2 CH.sub.2 ONO.sub.2, or --CH.sub.2 CH.sub.2 OCH.sub.2 ONO.sub.2.
- 3. The compound according to claim 1, wherein X=NR.sub.1c wherein R.sub.1c is a linear or branched C.sub.1 -C.sub.4 alkyl group.
- 4. A composition comprising the compound according to claim 1 or claim 2 and a pharmaceutically acceptable excipient.
- 5. A method for the treatment of inflammation comprising administering the composition of claim 4.
- 6. A method for the treatment of thrombosis comprising administering the composition of claim 4.
- 7. A method for the treatment of septic shock comprising administering the composition of claim 4.
Priority Claims (1)
Number |
Date |
Country |
Kind |
MI95A2263 |
Oct 1995 |
ITX |
|
Parent Case Info
This application is a 371 of PCT/EP96/04696 filed Oct. 29, 1996.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP36/04696 |
10/29/1996 |
|
|
4/29/1998 |
4/29/1998 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO97/16405 |
5/9/1997 |
|
|
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5621000 |
Arena et al. |
Apr 1997 |
|
5700947 |
Soldato |
Dec 1997 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
9201668 |
Feb 1992 |
WOX |
9530641 |
Nov 1995 |
WOX |
9716405 |
May 1997 |
WOX |